The estimated Net Worth of Gwenn Hansen is at least $1.83 Million dollars as of 30 July 2024. Dr Hansen owns over 8,957 units of Nurix Therapeutics stock worth over $1,154,224 and over the last 4 years he sold NRIX stock worth over $0. In addition, he makes $673,850 as Chief Scientific Officer at Nurix Therapeutics.
Dr has made over 27 trades of the Nurix Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 8,957 units of NRIX stock worth $212,908 on 30 July 2024.
The largest trade he's ever made was exercising 12,000 units of Nurix Therapeutics stock on 30 November 2020 worth over $10,080. On average, Dr trades about 2,139 units every 42 days since 2020. As of 30 July 2024 he still owns at least 48,558 units of Nurix Therapeutics stock.
You can see the complete history of Dr Hansen stock trades at the bottom of the page.
Dr. Gwenn M. Hansen Ph.D. is the Chief Scientific Officer at Nurix Therapeutics.
As the Chief Scientific Officer of Nurix Therapeutics, the total compensation of Dr D at Nurix Therapeutics is $673,850. There are 2 executives at Nurix Therapeutics getting paid more, with Dr. Arthur T. Sands having the highest compensation of $852,767.
Dr D is 50, he's been the Chief Scientific Officer of Nurix Therapeutics since . There are 6 older and no younger executives at Nurix Therapeutics. The oldest executive at Nurix Therapeutics, Inc. is Howard A. Simon J.D., Esq., SPHR, 62, who is the VP of Operations & Corp. Counsel.
Gwenn's mailing address filed with the SEC is C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA, 94158.
Over the last 4 years, insiders at Nurix Therapeutics have traded over $1,236,800 worth of Nurix Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Clay B Siegall, and Biomedical Innovation Maste.... On average, Nurix Therapeutics executives and independent directors trade stock every 15 days with the average trade being worth of $116,806. The most recent stock trade was executed by Christine Ring on 3 September 2024, trading 9,050 units of NRIX stock currently worth $42,173.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Nurix Therapeutics executives and other stock owners filed with the SEC include: